Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

TWYMEEG® sales continued to increase in Japan for the last quarter 2024 (October-December) by 17% over the prior quarter and by 154% over Q4 2023 TWYMEEG®’s FY 20241 revised forecast2 of JPY 7.9 billion (EUR…

Read this Press Release: Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

Poxel Announces its Financial Calendar for 2025

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with…

Read this Press Release: Poxel Announces its Financial Calendar for 2025

Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents Poxel announces the addition of a new resolution to the agenda…

Read this Press Release: Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership